Skip to content

Study · Animal study (in vivo) · mouse · 2020

12 results

The guanylate cyclase C agonist linaclotide ameliorates the gut-cardio-renal axis in an adenine-induced mouse model of chronic kidney disease.

Nanto-Hara F, Kanemitsu Y, Fukuda S, Kikuchi K, Asaji K, Saigusa D, Iwasaki T, Ho HJ, Mishima E, Suzuki T, Suzuki C, Tsukimi T and 9 more

Show all authors

Matsuhashi T, Oikawa Y, Akiyama Y, Kure S, Owada Y, Tomioka Y, Soga T, Ito S, Abe T

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association1 Feb 2020Cited by 73 (Europe PMC)

PMID31411705 (opens in a new tab)DOI10.1093/ndt/gfz126 (opens in a new tab)PepBankPUB-31411705
Source linkPubMedAsk about this study
Jump to 12 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study12

12 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In adenine-induced renal failure mice, linaclotide decreased plasma TMAO at 10 μg/kg.

    In plain wordsIn mice with adenine-induced renal failure, linaclotide decreased plasma TMAO.

    Peptide
    Linaclotide
    Outcome
    DecreasePlasma TMAO
    Study

    micen: not reported in source

    Adenine-induced renal failure
    Outcome group
    Uremic Toxins · Kidney and urinary
    Studied dose
    10 μg/kgAs given in this study (mice).

    Source sentences

    Summary
    Linaclotide decreased the plasma levels of TMAO at a clinically used low dose of 10 μg/kg in the adenine-induced RF mouse model.
    1 context sentence
    Summary · context
    Linaclotide, a guanylate cyclase C agonist, was administered to adenine-induced renal failure (RF) mice and changes in renal function and levels of gut-derived uremic toxins, as well as the gut microbiota community, were analyzed using metabolomic and metagenomic methods to reveal its cardiorenal effect.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In adenine-induced renal failure mice, linaclotide at 100 μg/kg improved renal function.

    In plain wordsIn mice with adenine-induced renal failure, linaclotide improved kidney function.

    Peptide
    Linaclotide
    Outcome
    IncreaseRenal function
    Study

    micen: not reported in source

    Adenine-induced renal failure
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    100 μg/kgAs given in this study (mice).

    Source sentences

    Summary
    At a high concentration of 100 μg/kg, linaclotide clearly improved renal function and reduced the levels of various uremic toxins.
    1 context sentence
    Summary · context
    Linaclotide, a guanylate cyclase C agonist, was administered to adenine-induced renal failure (RF) mice and changes in renal function and levels of gut-derived uremic toxins, as well as the gut microbiota community, were analyzed using metabolomic and metagenomic methods to reveal its cardiorenal effect.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In adenine-induced renal failure mice, linaclotide at 100 μg/kg reduced various uremic toxin levels.

    In plain wordsIn mice with adenine-induced renal failure, linaclotide reduced various uremic toxins.

    Peptide
    Linaclotide
    Outcome
    DecreaseUremic toxin levels
    Study

    micen: not reported in source

    Adenine-induced renal failure
    Outcome group
    Uremic Toxins · Kidney and urinary
    Studied dose
    100 μg/kgAs given in this study (mice).

    Source sentences

    Summary
    At a high concentration of 100 μg/kg, linaclotide clearly improved renal function and reduced the levels of various uremic toxins.
    1 context sentence
    Summary · context
    Linaclotide, a guanylate cyclase C agonist, was administered to adenine-induced renal failure (RF) mice and changes in renal function and levels of gut-derived uremic toxins, as well as the gut microbiota community, were analyzed using metabolomic and metagenomic methods to reveal its cardiorenal effect.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In choline-fed pro-atherosclerotic mice, linaclotide treatment reduced TMAO levels.

    In plain wordsIn mice fed choline to promote atherosclerosis, linaclotide reduced TMAO levels.

    Peptide
    Linaclotide
    Outcome
    DecreaseTMAO in choline-fed model
    Study

    micen: not reported in source

    Choline-fed pro-atherosclerotic model
    Outcome group
    Uremic Toxins · Kidney and urinary
    Studied dose
    Dose not stated

    Source sentences

    Summary
    A reduction in TMAO levels following linaclotide treatment was also observed in a choline-fed pro-atherosclerotic model.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In renal failure mice, linaclotide ameliorated renal inflammation.

    In plain wordsIn mice with renal failure, linaclotide reduced kidney inflammation.

    Peptide
    Linaclotide
    Outcome
    DecreaseRenal inflammation
    Study

    micen: not reported in source

    Adenine-induced renal failure
    Outcome group
    Inflammation markers · Kidney and urinary
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Linaclotide ameliorated renal inflammation and fibrosis and cardiac fibrosis, as well as decreased the expression of collagen I, transforming growth factor-β, galectin-3 (Gal-3) and ST2 genes.
    1 context sentence
    Summary · context
    Linaclotide, a guanylate cyclase C agonist, was administered to adenine-induced renal failure (RF) mice and changes in renal function and levels of gut-derived uremic toxins, as well as the gut microbiota community, were analyzed using metabolomic and metagenomic methods to reveal its cardiorenal effect.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In renal failure mice, linaclotide ameliorated renal fibrosis.

    In plain wordsIn mice with renal failure, linaclotide reduced kidney scarring.

    Peptide
    Linaclotide
    Outcome
    DecreaseRenal fibrosis
    Study

    micen: not reported in source

    Adenine-induced renal failure
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Linaclotide ameliorated renal inflammation and fibrosis and cardiac fibrosis, as well as decreased the expression of collagen I, transforming growth factor-β, galectin-3 (Gal-3) and ST2 genes.
    1 context sentence
    Summary · context
    Linaclotide, a guanylate cyclase C agonist, was administered to adenine-induced renal failure (RF) mice and changes in renal function and levels of gut-derived uremic toxins, as well as the gut microbiota community, were analyzed using metabolomic and metagenomic methods to reveal its cardiorenal effect.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In renal failure mice, linaclotide ameliorated cardiac fibrosis.

    In plain wordsIn mice with renal failure, linaclotide reduced heart scarring.

    Peptide
    Linaclotide
    Outcome
    DecreaseCardiac fibrosis
    Study

    micen: not reported in source

    Adenine-induced renal failure
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Linaclotide ameliorated renal inflammation and fibrosis and cardiac fibrosis, as well as decreased the expression of collagen I, transforming growth factor-β, galectin-3 (Gal-3) and ST2 genes.
    1 context sentence
    Summary · context
    Linaclotide, a guanylate cyclase C agonist, was administered to adenine-induced renal failure (RF) mice and changes in renal function and levels of gut-derived uremic toxins, as well as the gut microbiota community, were analyzed using metabolomic and metagenomic methods to reveal its cardiorenal effect.
  8. 08AnimalAnimal study (in vivo)Efficacy outcome

    In renal failure mice, linaclotide decreased expression of collagen I, transforming growth factor-β, galectin-3 and ST2 genes.

    In plain wordsIn mice with renal failure, linaclotide decreased the reported fibrosis-related gene expression.

    Peptide
    Linaclotide
    Outcome
    DecreaseFibrosis-related gene expression
    Study

    micen: not reported in source

    Adenine-induced renal failure
    Outcome group
    Fibrosis Markers · Kidney and urinary
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Linaclotide ameliorated renal inflammation and fibrosis and cardiac fibrosis, as well as decreased the expression of collagen I, transforming growth factor-β, galectin-3 (Gal-3) and ST2 genes.
    1 context sentence
    Summary · context
    Linaclotide, a guanylate cyclase C agonist, was administered to adenine-induced renal failure (RF) mice and changes in renal function and levels of gut-derived uremic toxins, as well as the gut microbiota community, were analyzed using metabolomic and metagenomic methods to reveal its cardiorenal effect.
  9. 09AnimalAnimal study (in vivo)Efficacy outcome

    In renal failure mice, linaclotide reduced plasma Gal-3 levels.

    In plain wordsIn mice with renal failure, linaclotide reduced plasma Gal-3.

    Peptide
    Linaclotide
    Outcome
    DecreasePlasma Gal-3
    Study

    micen: not reported in source

    Adenine-induced renal failure
    Outcome group
    Fibrosis Markers · Kidney and urinary
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Plasma levels of Gal-3 and ST2 were also reduced.
    1 context sentence
    Summary · context
    Linaclotide, a guanylate cyclase C agonist, was administered to adenine-induced renal failure (RF) mice and changes in renal function and levels of gut-derived uremic toxins, as well as the gut microbiota community, were analyzed using metabolomic and metagenomic methods to reveal its cardiorenal effect.
  10. 10AnimalAnimal study (in vivo)Efficacy outcome

    In renal failure mice, linaclotide reduced plasma ST2 levels.

    In plain wordsIn mice with renal failure, linaclotide reduced plasma ST2.

    Peptide
    Linaclotide
    Outcome
    DecreasePlasma ST2
    Study

    micen: not reported in source

    Adenine-induced renal failure
    Outcome group
    Fibrosis Markers · Kidney and urinary
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Plasma levels of Gal-3 and ST2 were also reduced.
    1 context sentence
    Summary · context
    Linaclotide, a guanylate cyclase C agonist, was administered to adenine-induced renal failure (RF) mice and changes in renal function and levels of gut-derived uremic toxins, as well as the gut microbiota community, were analyzed using metabolomic and metagenomic methods to reveal its cardiorenal effect.
  11. 11AnimalAnimal study (in vivo)Efficacy outcome

    In renal failure mice, linaclotide decreased the elevated F4/80-positive macrophage expression in small intestinal crypts.

    In plain wordsIn mice with renal failure, linaclotide reduced the increased macrophage marker in small intestinal crypts.

    Peptide
    Linaclotide
    Outcome
    DecreaseF4/80-positive macrophages in intestinal crypts
    Study

    micen: not reported in source

    Adenine-induced renal failure
    Outcome group
    Inflammation markers · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    F4/80-positive macrophages were abundant in small intestinal crypts in RF mice, and this increased expression was decreased by linaclotide.
    1 context sentence
    Summary · context
    Linaclotide, a guanylate cyclase C agonist, was administered to adenine-induced renal failure (RF) mice and changes in renal function and levels of gut-derived uremic toxins, as well as the gut microbiota community, were analyzed using metabolomic and metagenomic methods to reveal its cardiorenal effect.
  12. 12AnimalAnimal study (in vivo)Efficacy outcome

    In renal failure mice, linaclotide restored reduced colonic claudin-1 levels.

    In plain wordsIn mice with renal failure, linaclotide restored reduced colon claudin-1 levels.

    Peptide
    Linaclotide
    Outcome
    IncreaseColonic claudin-1
    Study

    micen: not reported in source

    Adenine-induced renal failure
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Reduced colonic claudin-1 levels were also restored by linaclotide, suggesting that linaclotide ameliorated the 'leaky gut' in RF mice.
    1 context sentence
    Summary · context
    Linaclotide, a guanylate cyclase C agonist, was administered to adenine-induced renal failure (RF) mice and changes in renal function and levels of gut-derived uremic toxins, as well as the gut microbiota community, were analyzed using metabolomic and metagenomic methods to reveal its cardiorenal effect.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:34 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.